Cargando…
Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics
The search for inherited cancer susceptibility factors is a major focus of epidemiologic cancer studies. Analyses of single-nucleotide polymorphisms (SNP) in a variety of genes revealed a correlation between a specific allele variant and cancer predisposition. Human mouse double-minute 2 protein (Md...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2453021/ https://www.ncbi.nlm.nih.gov/pubmed/18577987 http://dx.doi.org/10.1038/sj.bjc.6604441 |
_version_ | 1782157337128075264 |
---|---|
author | Stoehr, R Hitzenbichler, F Kneitz, B Hammerschmied, C G Burger, M Tannapfel, A Hartmann, A |
author_facet | Stoehr, R Hitzenbichler, F Kneitz, B Hammerschmied, C G Burger, M Tannapfel, A Hartmann, A |
author_sort | Stoehr, R |
collection | PubMed |
description | The search for inherited cancer susceptibility factors is a major focus of epidemiologic cancer studies. Analyses of single-nucleotide polymorphisms (SNP) in a variety of genes revealed a correlation between a specific allele variant and cancer predisposition. Human mouse double-minute 2 protein (Mdm2) is a cellular E3 ligase capable of ubiquitination and degradation of p53. Therefore, Mdm2 is a crucial factor of cell cycle control and cell survival. The Mdm2 promoter SNP309 was shown to increase Mdm2 expression and can, thereby, inhibit the p53 pathway. This SNP was found to be associated with increased risk and early onset of various malignancies. For prostate cancer no studies are reported to date. In a case–control study we determined the distribution of the Mdm2 SNP309 in 145 male subjects with prostate cancer and in 124 male controls without any malignancy using RFLP analysis. Cases and controls showed a similar distribution of the SNP (P=0.299). Genotype distribution showed neither an association with histopathological characteristics of the tumours nor with prognosis. Age at disease onset was also not modified by the SNP. This first study of the Mdm2 SNP309 in prostate cancer patients suggests no correlation between a certain allelic variant and an increased cancer risk. |
format | Text |
id | pubmed-2453021 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-24530212009-09-11 Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics Stoehr, R Hitzenbichler, F Kneitz, B Hammerschmied, C G Burger, M Tannapfel, A Hartmann, A Br J Cancer Clinical Study The search for inherited cancer susceptibility factors is a major focus of epidemiologic cancer studies. Analyses of single-nucleotide polymorphisms (SNP) in a variety of genes revealed a correlation between a specific allele variant and cancer predisposition. Human mouse double-minute 2 protein (Mdm2) is a cellular E3 ligase capable of ubiquitination and degradation of p53. Therefore, Mdm2 is a crucial factor of cell cycle control and cell survival. The Mdm2 promoter SNP309 was shown to increase Mdm2 expression and can, thereby, inhibit the p53 pathway. This SNP was found to be associated with increased risk and early onset of various malignancies. For prostate cancer no studies are reported to date. In a case–control study we determined the distribution of the Mdm2 SNP309 in 145 male subjects with prostate cancer and in 124 male controls without any malignancy using RFLP analysis. Cases and controls showed a similar distribution of the SNP (P=0.299). Genotype distribution showed neither an association with histopathological characteristics of the tumours nor with prognosis. Age at disease onset was also not modified by the SNP. This first study of the Mdm2 SNP309 in prostate cancer patients suggests no correlation between a certain allelic variant and an increased cancer risk. Nature Publishing Group 2008-07-08 2008-06-24 /pmc/articles/PMC2453021/ /pubmed/18577987 http://dx.doi.org/10.1038/sj.bjc.6604441 Text en Copyright © 2008 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Stoehr, R Hitzenbichler, F Kneitz, B Hammerschmied, C G Burger, M Tannapfel, A Hartmann, A Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics |
title | Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics |
title_full | Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics |
title_fullStr | Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics |
title_full_unstemmed | Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics |
title_short | Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics |
title_sort | mdm2-snp309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2453021/ https://www.ncbi.nlm.nih.gov/pubmed/18577987 http://dx.doi.org/10.1038/sj.bjc.6604441 |
work_keys_str_mv | AT stoehrr mdm2snp309polymorphisminprostatecancernoevidenceforassociationwithincreasedriskorhistopathologicaltumourcharacteristics AT hitzenbichlerf mdm2snp309polymorphisminprostatecancernoevidenceforassociationwithincreasedriskorhistopathologicaltumourcharacteristics AT kneitzb mdm2snp309polymorphisminprostatecancernoevidenceforassociationwithincreasedriskorhistopathologicaltumourcharacteristics AT hammerschmiedcg mdm2snp309polymorphisminprostatecancernoevidenceforassociationwithincreasedriskorhistopathologicaltumourcharacteristics AT burgerm mdm2snp309polymorphisminprostatecancernoevidenceforassociationwithincreasedriskorhistopathologicaltumourcharacteristics AT tannapfela mdm2snp309polymorphisminprostatecancernoevidenceforassociationwithincreasedriskorhistopathologicaltumourcharacteristics AT hartmanna mdm2snp309polymorphisminprostatecancernoevidenceforassociationwithincreasedriskorhistopathologicaltumourcharacteristics |